
==== Front
Noncoding RNA Res
Noncoding RNA Res
Non-coding RNA Research
2468-0540
KeAi Publishing

S2468-0540(24)00123-9
10.1016/j.ncrna.2024.07.003
Review Article
Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers
Li Yongxing abc1
Tang Xiaoqi a1
Wang Binpan a
Chen Ming chming1971@126.com
a⁎⁎
Zheng Ji jizheng023@aliyun.com
bcd⁎⁎⁎
Chang Kai changkai0203@tmmu.edu.cn
ad⁎
a Department of Clinical Laboratory Medicine, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, PR China
b Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, PR China
c School of Medicine, Chongqing University, Chongqing, 400030, PR China
d State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University (Third Military Medical University), Chongqing, 400038, PR China
⁎ Corresponding author. Department of Clinical Laboratory Medicine, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, PR China. changkai0203@tmmu.edu.cn
⁎⁎ Corresponding author. chming1971@126.com
⁎⁎⁎ Corresponding author. Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, PR China. jizheng023@aliyun.com
1 Y.L. and X.T. contributed equally to this work.

20 7 2024
12 2024
20 7 2024
9 4 13511362
29 2 2024
12 6 2024
18 7 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Prostate cancer (PCa) has the highest frequency of diagnosis among solid tumors and ranks second as the primary cause of cancer-related deaths. Non-coding RNAs (ncRNAs), such as microRNAs, long non-coding RNAs and circular RNAs, frequently exhibit dysregulation and substantially impact the biological behavior of PCa. Compared with circulating ncRNAs, ncRNAs loaded into exosomes are more stable because of protection by the lipid bilayer. Furthermore, exosomal ncRNAs facilitate the intercellular transfer of molecules and information. Increasing evidence suggests that exosomal ncRNAs hold promising potential in the progression, diagnosis and prognosis of PCa. This review aims to discuss the functions of exosomal ncRNAs in PCa, evaluate their possible applications as clinical biomarkers and therapeutic targets, and provide a comprehensive overview of the ncRNAs regulatory network in PCa. We also identified ncRNAs that can be utilized as biomarkers for diagnosis, staging, grading and prognosis assessment in PCa. This review offers researchers a fresh perspective on the functions of exosomal ncRNAs in PCa and provides additional options for its diagnosis, progression monitoring, and prognostic prediction.

Graphical abstract

In prostate cancer (PCa), non-coding RNAs (ncRNAs) are transferred from donor cells to recipient cells via exosomes and involved in gene expression through various mechanisms. Due to the regulative effects of exosomal ncRNAs on physiological and pathological processes, they are potential biomarkers and promising therapeutic tools in PCa.Image 1

Keywords

Biomarkers
Exosomes
Modulators
Non-coding RNAs
Prostate cancer
==== Body
pmc1 Introduction

Prostate cancer (PCa) has the highest diagnostic rate among male malignancies. Moreover, it ranks second among the leading causes of cancer-associated mortality in the United States [[1], [2], [3]]. Globally, approximately 10 million men have been diagnosed with PCa, and the incidence of metastatic PCa is increasing, leading to over 3.8 million deaths annually [[4], [5], [6]]. By 2040, this number is estimated to be at least twice as high as it is today [7,8]. Since the survival rate of PCa is strongly linked to early diagnosis [9], prostate-specific antigen (PSA) is used for mass screening of suspected patients. However, due to the non-cancer specificity, PSA often leads to unnecessary overdiagnosis and treatment [10]. Given the significant burden of PCa, it is crucial to explore its evolutionary mechanisms and identify potential diagnostic biomarkers and therapeutic tools.

After reticular cells were discovered to secrete vesicles containing biomolecules outside the cell [11], exosomes have emerged as the shining stars of liquid biopsies, displaying profound potential in the realm of cancer diagnosis and treatment. Once considered mere cellular waste bins, exosomes are now recognized as vital vehicles for transporting specific molecules between cells [11]. Exosomes comprise diverse types of biomolecules, including nucleic acids, proteins, lipids, sugars and metabolites [12]. Furthermore, non-coding RNAs (ncRNAs) contained within exosomes, are enriched and more stable than circulating ncRNAs because of the protection provided by the lipid bilayer [13,14]. These exosomal ncRNAs have been found to modulate multiple cellular processes in malignancies by regulating gene expression [[15], [16], [17]]. In addition, molecular and cellular biological studies of PCa have emphasized the key players in its progression [18,19]. Owing to their unique advantages and functions, exosomal ncRNAs serve as invaluable resources for gaining novel insights into PCa development and potential guides for its diagnosis and treatment.

In this review, we present a brief overview of exosomes and their components. Moreover, we emphasize the modulatory functions of exosomal ncRNAs in the initiation, growth, progression, and therapeutic resistance of PCa, with attention to their possible role as promising biomarkers. We also explore the clinical utilities of exosomal ncRNAs in PCa.

2 Exosomes

Exosomes are the most extensively investigated subset among extracellular vesicles (EVs), varying in size from 30 to 150 nm. They are produced by both eukaryotic cells and prokaryotic cells and can be found in all body fluids [20,21]. These vesicles are generated via an endosomal degradation pathway and cargo inside, on or outside cell can enter exosomes, supporting the essential function of exosomes in intercellular communication [20,22]. While the selective packaging mechanism of exosomes is still unknown, it has been demonstrated that exosomes from different sources or the same cells under different conditions carry a unique content profile [23]. This profile reflects the constituents and current status of the source and may indicate a modulatory selective packaging. Therefore, exosomes have demonstrated potential as modulators and biomarkers of various diseases.

Exosomes contain diverse components including proteins, lipids, nucleic acids, metabolites and small molecules. Proteins, partly originating from the cell membrane, endosomal membrane and cytoskeletal components [24], have been reported to regulate cancer progression [25,26] and serve as biomarkers for diagnostic and prognostic purposes [27,28]. Exosomal lipids are primarily located in the exosomal membrane and play a major role in exosomal formation and homeostasis in recipient cells [27]. They have also been found to modulate cancer and aid diagnosis because of their unique profiles [[29], [30], [31], [32]]. In addition, exosomes also contain nucleic acids such as DNAs and RNAs. It has been demonstrated that the number of DNAs with more bases is relatively higher in larger exosomes than in smaller exosomes [33]. This may indicate that small nucleotides are the most nucleic acids in exosomes. The ncRNAs consisting of dozens to over 200 nucleotides constitute over 98 % of the genome and are abundant in exosomes due to their short length [34]. They regulate gene expression by interacting with mRNAs, remodeling chromatin and cooperating with other biomolecules, thus constructing multiple regulatory networks that modulate the levels of a variety of fundamental protein effectors [35]. The relative abundance and function of ncRNAs in exosomes make them the principal players in cancer modulation [[15], [16], [17]].

The ncRNAs encompass various types of RNA molecules, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) [36]. MiRNAs, serving as short ncRNAs of roughly 22 nucleotides in length, are also the most common ncRNA type transported by exosomes and function by engaging in interactions with mRNAs [37]. LncRNAs are longer than 200 nucleotides and exhibit extensive functional diversity. They can guide chromatin-modifying complexes to target gene promoters and affect transcriptional regulation, as well as bind to miRNAs to modulate molecular functions [38]. CircRNAs are more than 200 nucleotides in length like lncRNAs and are protected from exonuclease degradation due to the closed circular structures and the absence of polyadenylated tail [39]. Therefore, circRNAs in mammalian cells have a longer half-life that is approximately 2.4 times longer than linear RNAs [40] and exosomes exhibit a higher proportion of circRNAs to linear RNAs, with a ratio that is approximately 6 times higher than in cells [41]. Furthermore, circRNAs act as sponges and scaffolds for specific proteins and can be translated to perform specific functions in cancer [17].

3 Exosomal ncRNAs as modulators in PCa

Exosomes affect initiation, growth, development and treatment of cancer by facilitating cellular communication [42]. There is growing evidence indicating that exosomal ncRNAs are the major contributors to these effects. Exosomal ncRNAs can influence the levels of downstream target mRNAs, genes or proteins, altering various signaling pathways (Table 1). Subsequently, they trigger a range of physiological and pathological processes, including angiogenesis, proliferation, apoptosis, migration, invasion, phenotypic transformation, bone microenvironment regulation, and therapy resistance (Fig. 1). Therefore, comprehending the role of exosomal ncRNAs could offer a valuable perspective on PCa.Table 1 Molecular mechanisms of exosomal ncRNAs in modulation of prostate cancer.

Table 1Process	Types	ncRNAs	Signaling Pathways and Targets	
Initiation	miRNAs	miR-27a-3p [48], miR-21 [[51], [52], [53], [54],121] and let-7b [55]	VEGF [49,56,57], PTEN/AKT [54] and PTEN/ERK [54] pathway	
lncRNAs	/	/	
circRNAs	circRNA HIPK3 [150]	BMI-1 [151]	
Growth	miRNAs	miR-183 [65], miR-217 [70], miR-23b-3p [70], miR-143 [141], miR-205 [74], miR‐95 [77], miR-153 [85], miR-99b-5p [61], miR-888 cluster [88], miR-1246 [98], miR-26a [99], miR-424 [104], miR-31 [121] and miR-145 [121]	PI3K/AKT [62,63,78,79], NF-κB [62,64], Rho [75,76], STAT3 [86,87,105], TGF-β and mTOR [100] pathway; EZH2 [89]	
lncRNAs	MYU [135], lncAY927529 [139] and PCSEAT [141]	NF-κB [140] and PI3K/AKT [136] pathway; c-Myc [135]	
circRNAs	circRNA HIPK3 [150], circ_0044516 [154] and circ-XIAP [161]	Wnt/β-catenin pathway [155]; BMI-1 [151] and TPD52 [161]	
Progression	miRNAs	miR-27a-3p [117], miR-99b-5p [61], miR-183 [65], miR-217 [70], miR-23b-3p [70], miR-143 [141], miR-205 [74], miR‐95 [77], miR-153 [85], miR-146a-5p [94], miR-26a [99,117], miR-1246 [98], miR-888 cluster [88], miR-125b [101], miR-130b [101], miR-141-3p [108], miR-155 [101], let-7b [55], miR-424 [104], miR-375 [110], miR-940 [113], miR-1275 [116], miR-92a-1-5p [119], miR-31 [121], miR-145 [121] and miR-21 [55,121]	PI3K/AKT [98,103,120,142], NF-κB [118], Rho [114,115], STAT3 [86,87,105,107], TGF-β [120], EGFR [94,98], mTOR [100], Lats2/YAP [101], MAPK [108], MEK/ERK [120] and Wnt/β-catenin [142] pathway; EZH2 [89], p53 [127], PDCD4 [101], RUNX2 [111,116,117] and FAM134A [113]	
lncRNAs	MYU [135], lncAY927529 [139], PCSEAT [141], HOXD-AS1 [143] and NEAT1 [145]	NF-κB [140], PI3K/AKT [136] and Wnt/β-catenin [142] pathways; c-Myc [135], FOXM1 [143] and PTBP2/SFPQ complex [145]	
circRNAs	circRNA HIPK3 [150], circ_0044516 [154], circ_0081234 [157] and circ-XIAP [161]	Wnt/β-catenin [155] and MAPK [158] pathway; BMI-1 [151] and TPD52 [161]	
Therapy resistance	miRNAs	miR-31 [121], miR-145 [121], miR-21 [121], miR-27a [127], miR-423-5p [130] and miR-34a [131,132]	STAT3 [129], TGF-β [130], NF-κB [133] and PI3K/AKT [134] pathway	
lncRNAs	LINC01213 [148]	Wnt/β-catenin pathway [148]	
circRNAs	circ-XIAP [150]	TPD52 [161]	

Fig. 1 The modulatory mechanisms of exosomal ncRNAs in PCa. Exosomes derived from diverse cell types transport non-coding RNAs, which in turn modulate the expression of downstream genes, target mRNAs or proteins and alter various signaling pathways. The exosomal ncRNAs trigger a cascade of physiological and pathological events, encompassing angiogenesis, proliferation, apoptosis, migration, invasion, phenotypic transformation, bone microenvironment regulation and therapeutic resistance. Ultimately, these processes affect the occurrence, growth, development and treatment of PCa.

Fig. 1

3.1 Exosomal miRNAs in PCa

3.1.1 Exosomal miRNAs in PCa initiation

The first step in cancer development is initiation, in which angiogenesis provides oxygen and nutrients and eliminates metabolic waste and carbon dioxide from tumor cells [43]. Angiogenesis, which is the neovascularization from the original ones, is typically activated transiently in response to various stimuli, including wound healing and the female reproductive cycle [44]. However, the angiogenic switch is always activated in cancer to support the growth of cancer cells. Without the support of angiogenesis, the cancer cells would only reside within 100 μm of capillary blood vessels and could not expand [45]. Angiogenesis is regulated by several growth factors and cytokines, such as vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α [15]. Tumor-derived exosomes can regulate angiogenesis through proangiogenic biomolecules, which induce or inhibit angiogenesis by modulating angiogenic signaling pathways in endothelial cells [46,47].

Exosomal miRNAs are significant modulators of angiogenesis in PCa, involving multiple signaling pathways dominated by VEGF. Exosomal miR-27a-3p is overexpressed in the PC-3 PCa cell line, which induces angiogenesis by enhancing endothelial tube formation [48]. In the proangiogenic process, miR-27a-3p directly targets tissue factor pathway inhibitor (TFPI), inhibits the expression of TFPIα, reduces the phosphorylation of VEGFR2 at residue K951 [49], and then restrains endothelial cell migration [50]. Therefore, miR-27a-3p may induce angiogenesis through the miR-27a-3p/TFPI/VEGF pathway. Additionally, the HIF-1α/VEGF pathway is another common regulatory target. Exosomal miR-21 is upregulated in patients with PCa and DU145 PCa cell line [[51], [52], [53], [54]]. It targets phosphatase and tensin homolog deleted on chromosome ten (PTEN), activates AKT and extracellular regulated kinases (ERK) 1/2, upregulates HIF-1α and VEGF [54], and promotes angiogenesis via HIF-1α/VEGF pathway. Similarly, exosomal let-7b is overexpressed in PC-3 cell-derived exosomes, increased in recipient cells, and promotes tube-like structure formation, which is an essential step during neoangiogenesis in human umbilical vein endothelial cells (HUVEC) [55]. Moreover, let-7b is a hypoxia-responsive miRNA that modulates the expression of VEGF by targeting argonaute 1 (AGO1) [56,57], indicating that the HIF-1α/let-7b/AGO1/VEGF pathway might be the potential mechanism of angiogenesis in PCa. In conclusion, exosomal miRNAs engage in PCa angiogenesis through various signaling pathways dominated by VEGF.

3.1.2 Exosomal miRNAs in PCa growth

With sustained angiogenesis, the tumor acquires sufficient support for growth by regulating cell proliferation and apoptosis. Cell proliferation refers to the controlled growth and division of cells, leading to the generation of new daughter cells and an overall increase in cell population. Apoptosis is an automatic and orderly cell death program that is crucial for cell consumption. Thus, cell proliferation and apoptosis are essential processes in tumor growth and correlate with a rise in the number of malignant cells [45]. These crucial cellular processes are regulated by various physical and chemical signals. Exosomal miRNAs have been reported to modulate cell proliferation and apoptosis in various cancers, including colorectal [58], gastric [59] and ovarian [60] cancers.

Exosomal miRNAs are involved in modulating cell proliferation as either tumor promoters or suppressors through a series of signaling pathways in PCa. One such tumor suppressor is miR-99b-5p, which is upregulated in exosomes obtained from human bone marrow mesenchymal stem cells (hBMSCs). This elevation significantly inhibited PCa growth in vivo and in vitro by downregulating insulin-like growth factor-1 receptor (IGF1R) [61]. IGF1R mediates the phosphoinositide 3-kinase (PI3K)/AKT [62,63] and nuclear factor-kappaB (NF-κB) pathways [62], promoting cell proliferation in PCa [62,64]. Another miRNA, miR-183, is upregulated in LNCaP and PC-3 cell-derived exosomes and enhances cell proliferation by downregulating tropomyosin1 (TPM1) [65], which acts as a tumor suppressor in PCa [66,67]. The underlying mechanism of TPM1 in PCa requires further investigation, but the TPM1/mitogen-activated protein kinase kinase (MEK)/ERK pathway and TPM1/NF-κB pathway in colorectal cancer [68] and osteosarcoma [69] may offer possible pathways by which TPM1 functions in PCa.

The modulation of apoptosis by exosomal miRNAs in PCa involves multiple pathways. Exosomal miR-217 is significantly upregulated in the serum of patients with PCa and acts as an oncogenic factor by inhibiting apoptosis, whereas miR-23b-3p is significantly downregulated and acts as a pro-apoptotic factor [70]. However, how miR-217 and miR-23b-3p function in PCa remains unexplored. Notably, miR-217 has oncogenic and anti-tumor effects. MiR-217 significantly promotes apoptosis in chemotherapy-treated PC-3 cells by regulating polo-like kinase 1 (PLK1) and protein tyrosine kinase 2 (PTK2) expression [71]. Other studies have suggested several potential mechanisms, including PLK1/androgen receptor (AR) [72] and PTK2/PI3K/AKT [73] pathways. The dual roles of miR-217 on apoptosis were observed in PC-3 cells, which excluded the possibility of cell line diversity and suggested that the effect of chemotherapy may be the underlying reason. After chemotherapy, intracellular molecules in PC-3 cells may alter, resulting in a reduction in the levels of the miR-217 initial target and an elevation of new targets such as PLK1 and PTK2, or the activation of other complicated mechanisms. This suggests that chemotherapy may trigger the conversion of biomolecules from pro-cancer molecules to anti-cancer molecules.

MiRNAs in exosomes derived from other non-cancerous cells also regulate apoptosis. For instance, hBMSCs-derived exosomes overexpressing miR-205 promote apoptosis in vivo and tumor growth in vitro by suppressing rhophilin-2 (RHPN2) [74]. By targeting RHPN2, miR-205 indirectly regulates apoptosis via the Rho pathway [75,76]. MiR-95, which is significantly increased in tumor-associated macrophages (TAMs)-derived exosomes, directly targets JunB, thereby inhibiting PCa cell apoptosis [77]. JunB is functionally relevant for increased proliferation and decreased senescence in PCa through interaction with PI3K/AKT pathway [78,79]. Overall, exosomal miRNAs primarily modulate PCa growth via PI3K/AKT, AR and Rho pathways.

3.1.3 Exosomal miRNAs in PCa progression

PCa undergo certain changes as they progress, where cancer cells become more aggressive, non-cancerous cells change their phenotype, and the tumor microenvironment is remodeled. These characteristics enable tumors to alter their microenvironment and grow in distant organs, thereby promoting their survival and development. Invasion and migration increase cell mobility, allowing tumor cells to penetrate the vascular matrix. Recent studies on the new hallmarks of cancer have shown that phenotypic transformation is a crucial factor in neoplastic development [43]. Additionally, the “seed and soil” theory suggests that the emergence of a bone pre-metastasis niche creates favorable conditions for PCa metastasis [80].

Cumulative evidence has revealed that exosomes have emerged as a novel messaging system in organisms, mediating cell-cell and inter-organ communication in tumor progression. Specifically, biologically functional molecules inside exosomes are transferred to recipient cells, facilitating tumor progression by influencing invasion [81], migration [82], phenotypic transformation [83] and bone microenvironment regulation [84].

Cell invasion and migration are hallmark features of aggressive cancer and are significantly influenced by exosomes, particularly exosomal miRNAs. Exosomes facilitate the detachment of tumor cells in situ and their transport to other sites via the bloodstream or lymphatic system [11]. In PCa, exosomal miRNAs have been identified as oncogenic factors that promote cell invasion and migration through multiple pathways. For instance, in the DU145 and PC3 cell lines with high Gleason score (GS ≥ 7), miR-153 is overexpressed and transferred through exosomes, promoting cell invasion and migration by regulating kruppel-like factor 5 (KLF5) [85]. KLF5 is deleted and plays a suppressor role by inhibiting the IGF1/signal transducer and activator of the transcription 3 (STAT3) pathway in PCa [86,87]. Exosomal miR-888 and its cluster members are enriched in PC3-ML cells. MiR-888 inhibits KLF5, retinoblastoma-like 1 (RBL1), tissue inhibitor of metalloproteinase 2 (TIMP2) and SMAD4 levels and enhances cell migration and invasion in vitro [88]. KLF5 is also a target of exosomal miR-153 [87]. RBL1 interferes with the enhancer of zeste homolog 2 (EZH2) and is involved in oncogenic processes [89]. TIMP2 inhibits cell migration, invasion and cancer cell-mediated tissue remodeling [90], possibly through the PI3K/AKT pathway [91]. SMAD4 regulates cell invasion and motility in PCa [92], likely through the SMAD4/TGF-β pathway [93]. Overall, low levels of KLF5, RBL1, SMAD4, and TIMP2 levels are associated with PCa progression.

Exosomal miRNAs also act as suppressors of cell invasion and migration. Cancer-associated fibroblasts (CAFs) also contribute to PCa progression. CAFs-derived exosomes contain miR-146a-5p, which is taken up by LNCaP and DU145 cells and inhibits epidermal growth factor receptor (EGFR)/ERK pathway [94]. This inhibition results in a decrease in cell migration and invasion of PCa [95]. In addition, EGFR is related to biochemical relapse and high GS in PCa [96]. Therefore, exosomal miRNAs modulate cell invasion and migration in PCa through various pathways, including the IGF/STAT3, RBL1/EZH2, TGF-β, PI3K/AKT and EGFR/ERK pathways.

Moreover, exosomal miRNAs are associated with cellular phenotypic transformations that enhance PCa cell aggressiveness. Epithelial-mesenchymal transition (EMT) is a well-known phenotypic transformation and a conserved developmental program controlled by several signaling pathways. It confers metastatic properties and enhances cancer aggressiveness by regulating cell activity, invasion and apoptosis [97].

Exosomal miRNAs are also involved in PCa EMT. The miR-1246 selectively is secreted into exosomes in PCa. It targets EMT-related genes, inhibits EMT, and regulates other cellular processes via the EGFR and PI3K/AKT pathways [98]. Likewise, Exosomal miR-26a is increased in LNCaP cells and significantly downregulates the expression of EMT-related factors in recipient cells [99] by regulating the la-related proteins 1 (LARP1)/mechanistic target of rapamycin (mTOR) pathway [100].

Other phenotypic transformations such as mesenchymal-epithelial transition (MET) and neoplastic transformations also occur in the tumor microenvironment. Co-culture with C4–2B and PC-3 cell-conditioned media induces phenotypic transformation in stem cells, resulting in the formation of prostate-like neoplastic lesions. This transformation is facilitated by exosomes, which upregulate oncogenic factors (miR-125b, miR-130b, and miR-155) and downregulate tumor suppressors (large tumor suppressor homolog 2 (LATS2) and programmed cell death protein 4 (PDCD4)) [101]. The LATS2/yes associated protein (YAP) pathway is critical for tissue homeostasis in PCa [102], and the PI3K/AKT pathway is associated with the expression of PDCD4 [103]. Additionally, exosomal miRNAs are involved in the acquisition of stem cell-like and tumorigenic properties in prostate epithelial cells. In patients with metastatic PCa, there is a higher frequency of circulating miR-424-positive exosomes compared to those with primary tumors and benign prostatic hyperplasia (BPH). MiR-424-loaded exosomes promote stem cell-like properties and tumor initiation, contributing to tumorigenesis in recipient cells [104]. Meanwhile, miR-424 promotes tumorigenic traits via the miR-424/constitutive photomorphogenic 1 (COP1)/STAT3 axis [105].

Phenotypic transformation is also present in the immune system, not only in the mesenchymal and epithelial cells. Overexpressed let-7b in PC-3 cell-derived exosomes can be transferred to THP-1 monocytes, inducing TAM-like polarization [55], which facilitates tumor cell growth [106]. These effects of let-7b are attributed to the suppressor of cytokine signaling 1 (SOCS1)/STAT3 pathway [107]. To conclude, exosomal miRNAs modulate the transformation of cell phenotypes and enhance malignant activity through the EGFR, PI3K/AKT, LARP1/mTOR, Lats2/YAP, and STAT3 pathways.

PCa frequently results in the development of bone metastasis. Exosomes are essential in the preparation of bone pre-metastatic niches. They contain miRNAs that stimulate the formation of a metastatic microenvironment. Exosomal miR-141-3p is overexpressed in MDA PCa 2b cells. It can enter osteoblasts and stimulate their activity. This can lead to bone metastasis and osteogenic damage in PCa. The underlying mechanism of miR-141-3p involves the inhibition of deletion of liver cancer-1 (DLC1) and the activation of the mitogen-activated protein kinase (MAPK) pathway [108]. DLC1 modulates the Rho pathway and suppresses the invasion of highly metastatic PCa cells [109]. Similarly, exosomal miR-375 is identified to promote osteoblast activity [110] via the miR-375/runt-related transcription factor 2 (RUNX2) pathway [111]. RUNX2 is a major modulator of osteoblast activity and related to the metastatic traits of C4–2B cells [112]. In addition, C4–2B cell-derived exosomal miR-940 enhances osteoblastic differentiation in human mesenchymal stem cells by the modulation of Rho GTPase-activating protein 1 (ARHGAP1) and family with sequence similarity 134 member A (FAM134A) [113]. ARHGAP1 is a potential tumor suppressor that mediates osteoblastic differentiation via the Rho pathway [114,115], whereas FAM134A is an oncogenic factor in tumor metastasis, and its physiological function in osteogenesis remains unclear [113]. The transfer of miR-1275 from PC-3 cells to osteoblasts via exosomes significantly enhances osteoblast proliferation by inhibiting sirtuin 2 (SIRT2) and increasing RUNX2 expression [116]. Collectively, exosomal miRNAs have a critical function in PCa bone metastasis.

In addition to osteoblastic lesions, exosomal ncRNAs have been implicated in osteolytic loss. RM1-BM PCa cell-derived exosomes show increased expression of miR-26a-5p, miR-27a-3p and miR-30e-5p. These miRNAs suppress osteogenesis and osteoblast differentiation [117]. The miR-26a-5p targets bone morphogenetic protein 2 (BMP-2), which was reported to activate NF-κB mediated BMP-2-SMAD signaling cascade [118]. Both miR-26a-5p and miR-27a-3p can rejuvenate the level of t RUNX2 [117]. Exosomes derived from PCa cells regulate bone homeostasis, leading to osteoclastic lesions and the promotion of bone tumor growth. MiR-92a-1-5p is overexpressed in MDA PCa 2b cell exosomes and transferred to osteoclasts, promoting osteoclast differentiation through regulating collagen type I alpha 1 (COL1A1) [119]. COL1A1 might be regulated by TGF-β pathway, EGFR/MEK/ERK pathway and PI3K/AKT pathway [120], which implies the involvement of these pathways in the regulation of osteoclastic lesions.

3.1.4 Exosomal miRNAs in PCa therapy resistance

Therapy resistance inevitably presents a complex challenge in PCa, including resistance to androgen deprivation therapy (ADT) and chemotherapy. ADT is the recommended primary therapy for PCa and can improve patient prognosis to a certain extent. However, almost all androgen-sensitive PCa finally becomes androgen-resistant, leading to castration-resistant PCa (CRPC) that can metastasize to distant organs. Exosomes are pivotal in modulating therapy resistance and promoting PCa progression by conveying anti- and pro-tumor signals [27]. Consequently, exosomes can positively or negatively impact therapy resistance by delivering their cargo, indirectly affecting treatment and prognosis.

Mesenchymal-like PCa cells (Mes-PCa)-derived exosomes are involved in promoting mesenchymal characteristics in recipient cells, resulting in resistance to enzalutamide. Genetic analysis of the recipient cells revealed the downregulation of AR and AR-regulated genes, which may be associated with miR-31, miR-145 and miR-21. Mes-PCa-derived exosomes deliver these miRNAs to recipient cells where they target the AR pathway. The upregulation of these miRNAs is associated with message delivery by Mes-PCa-derived exosomes [121]. MiR-31 and miR-21 act as oncogenic factors in regulating therapeutic resistance [[122], [123], [124]], while miR-145 plays a tumor suppressor role and inhibits chemo-radio-resistance [125,126]. Although these miRNAs are all upregulated in Mes-PCa-derived exosomes, the effect of Mes-PCa-derived exosomes is mainly attributed to miR-31 and miR-21.

Non-cancerous cell-derived exosomes implicate in chemoresistance as well. For example, primary prostate fibroblasts (PSC-27)-derived exosomes carrying miR-27a promote chemoresistance of PC-3 cells by inhibiting p53 [127]. The inhibition of p53 can confer resistance to chemotherapeutic drugs [128], activate the STAT3 pathway, and promote tumor progression [129]. MiR-423-5p is overexpressed in CAF-derived exosomes and modulates drug resistance by targeting gremlin 2 via TGF-β pathway [130].

Moreover, exosomal miRNAs implicate in upregulating chemotherapy sensitivity. For example, exosomes derived from docetaxel-resistant PC-3 and 22Rv1 cells decrease levels of miR-34a, which leads to increased docetaxel resistance by upregulating B-cell lymphoma-2 [131,132]. It is related to NF-κB [133], PI3K/AKT [134] and other pathways. Overall, exosomal miRNAs derived from different cells have a significant impact on regulating therapy resistance via the AR, STAT3, TGF-β, NF-κB and other signaling pathways, contributing to chemoresistance and sensitivity to chemotherapy.

3.2 Exosomal lncRNA in PCa

3.2.1 Exosomal lncRNAs in PCa growth

Exosomal lncRNAs act as miRNA sponges and indirectly regulate PCa growth. They have been shown to exert significant effects on cell proliferation and apoptosis. Exosomal lncRNA MYU complements miR-184, resulting in the upregulation of c-Myc level, which subsequently stimulates the proliferation of PC-3 cells [135]. The c-Myc maintains a high cell proliferation rate and cooperates with the PI3K/AKT pathway [136] to promote PCa cell survival [137,138]. Additionally, the upregulation of exosomal lncAY927529 inhibits apoptosis by positively regulating C-X-C motif chemokine ligand-14 level [139]. It promotes M2 macrophage polarization through the NF-κB pathway and contributes to LNCaP and PC-3 cell proliferation, invasion, colony formation and tumor growth [140].

3.2.2 Exosomal lncRNAs in PCa progression

Exosomal lncRNAs, boasting over 200 nucleotides, possess distinctive nucleotide sequences that allow them to complement and pair with corresponding miRNAs, thereby exerting an indirect influence on gene expression and modulating the progression of PCa. For instance, exosomal lncRNA PCSEAT, which is overexpressed in patients with PCa, is transmitted to promote migration and proliferation of recipient cells via exosomes. PCSEAT modulates EZH2 by interacting with miR-143-3p and miR-24-2-5p [141]. EZH2 plays a crucial role in activating the PI3K/AKT/mTOR and Wnt/β-catenin pathways [142].

Exosomal lncRNAs induce phenotypic transformation in PCa. Exosomal lncRNA HOXD-AS1 is increased in LNCaP-Bic and LNCaP-AI cell-derived exosomes. In recipient cells, HOXD-AS1 competitively binds to miR-361-5p, upregulates forkhead box protein M1 (FOXM1), and induces a metastasis-associated phenotype in vitro and in vivo [143]. The HIF-1α/FOXM1 pathway is mediated by EMT in PCa [133]. Moreover, FOXM1 may also be involved in the modulation of the AR pathway through interaction with the AR [144].

In the bone microenvironment, exosomal lncRNAs regulate osteogenic activity. Exosomal lncRNA nuclear-enriched abundant transcript 1 (NEAT1) is transported to hBMSCs, which upregulates RUNX2 level by interacting with miR-205-5p [145]. Additionally, the overexpression of RUNX2 could be partly attributed to the splicing factor proline- and glutamine-rich (SFPQ)/polypyrimidine tract-binding protein 2 (PTBP2) axis [145]. Additionally, exosomal HOXD-AS1 enhances osteolytic loss and tumor metastasis in the microenvironment via the miR-361-5p/FOXM1 axis [143]. FOXM1 is involved in a metastasis-related gene network, including those related to cellular adhesion and bone microenvironment [146].

3.2.3 Exosomal lncRNAs in PCa therapy resistance

Exosomal lncRNAs modulate androgen sensitivity in PCa, ultimately influencing the efficacy of ADT. Androgens are key drivers of prostate growth and are known to contribute to tumor progression. As androgen sensitivity changes in tumor cells, PCa can progress to CRPC and become androgen-independent [147]. Androgen-independent PCa cell-derived exosomes enhance the acquisition of androgen independence. This effect is mediated in part by overexpression of the LINC01213, which confers androgen deprivation tolerance by activating the Wnt/β-catenin pathway [148]. Activation of this pathway is more commonly observed in CRPC than in treatment-naïve PCa, and its inhibitors can reduce therapy resistance in PCa [149].

3.3 Exosomal circRNA in PCa

3.3.1 Exosomal circRNAs in PCa initiation

Exosomal circRNAs modulate angiogenesis in PCa by regulating miRNAs. For example, circHIPK3 interacts with miR-212 [150] and its overexpression leads to upregulation of B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) and inhibition of angiogenesis in PCa [151]. BMI-1 significantly affects the initiation and development of PCa [152]. Moreover, BMI-1 has been shown to promote angiogenesis via the NF-κB pathway in gliomas [153], which may be a potential mechanism of BMI-1 in PCa.

3.3.2 Exosomal circRNAs in PCa growth

Exosomal circRNAs also implicate in modulating tumor growth by acting as miRNA sponges in PCa. Circ_0044516 overexpression in exosomes downregulates miR-29a-3p and enhances the proliferation as an oncogenic factor in PCa [154]. MiR-29a-3p regulates cell proliferation by mediating the classical Wnt/β-catenin pathway in PCa [155]. Exosomal circHIPK3 reduces apoptosis via the circHIPK3/miR-212/BMI-1 axis [150]. The inhibition of BMI-1 impairs apoptosis-related protein expression via the ubiquitination pathway and promotes apoptosis in PCa [156].

3.3.3 Exosomal circRNAs in PCa progression

Exosomal circRNAs modulate PCa progression by acting as miRNA sponges. Exosomes derived from patients with PCa and spinal metastasis (SM) showed higher expression levels of circ_0081234 compared to those without SM. Overexpression of circ_0081234 promoted malignant activity by increasing MAP3K1 levels as a miR-1 sponge [157]. MAP3K1 is part of the MAPK/MEK/ERK pathway, which is a significant signaling pathway in PCa EMT [158]. By the circHIPK3/miR-212/BMI-1 axis, exosomal circHIPK3 enhances cell viability, migration and invasion [150]. BMI-1 also modulates cell migration and invasion in PCa progression [156,159,160].

3.3.4 Exosomal circRNAs in PCa therapy resistance

Exosomal circRNAs implicate in the upregulation of chemoresistance via message delivery. Docetaxel (DTX)-resistant PCa cell-derived exosomes enhance DTX resistance, in which circ-XIAP is overexpressed, directly targets miR-1182, and increases TPD52 level [161]. TPD52 avoids apoptosis in response to androgen deprivation by activating the PI3K/AKT and STAT3 pathways [[162], [163], [164]].

Signaling pathways mediated by miRNAs, lncRNAs and circRNAs in exosome-derived PCa cells are not only involved in a single cellular activity. For example, the PI3K/AKT pathway is associated with cellular proliferation, apoptosis, invasion, migration, phenotypic transformation, regulation of the bone microenvironment and therapy resistance in PCa. Therefore, exosomal ncRNAs are delivered and target the same or correlated signaling pathways, which in turn affect cellular activity. This establishes a complicated modulatory network in PCa and sheds new light on the pathogenesis of PCa. Overall, the regulatory mechanisms of PCa are diverse and every cellular process cannot be viewed unilaterally. Additional exploration is necessary to reveal the underlying mechanisms and crosstalk among the aforementioned pathways.

4 Exosomal ncRNAs as biomarkers in PCa

Due to their capacity to regulate a wide range of cellular processes, exosomal ncRNAs serve as valuable biomarkers for diagnosis, staging, grading and prognosis assessment. The levels of exosomal ncRNAs reflect the status of donor and recipient cells due to the specific roles of exosomal ncRNAs in PCa. Profiling and quantifying exosomal ncRNAs have shown differential expression levels among healthy individuals, patients with BPH, patients with androgen-sensitive PCa and patients with CRPC [12,165,166]. Therefore, exosomal ncRNAs are of the utmost importance in providing precise diagnostic, staging, grading and prognostic biomarkers for PCa (Table 2).Table 2 Biomarkers of exosomal ncRNAs in prostate cancer.

Table 2Biomarker Type	Role	Source	
Urine	Plasma	Serum	
Diagnostic biomarkers	Distinguish PCa from HS	miR-19b [172], miR-21 [51,52], miR-141-5p [52], miR-375 [171], miR-486-5p [171], miR-451a [171], miR-486-3p [171], miR-196a-5p [170], miR-501-3p [170], let-7c [51], miR-574-3p [52] and miR-2909 [174]	miR-125a-5p [175], miR-141-5p [175] and lncAY927529 [139]	miR-141 [52,176,177], miR-212 [150], HIPK3 [150] and circ_0044516 [154]	
Distinguish PCa from BPH	miR-145 [173], miR-1290 [173], miR-2909 [174] and lncRNA-p21 [181]	miR-21-5p [53] and miR-200c-3p [53]	/	
Distinguish PCa from negative prostate biopsy	PCA3 [178] and MALAT1 [178]	/	/	
Staging and grading biomarkers	Identify metastatic PCa	miR-375 [171,173] and miR-1290 [171,173]	/	miR-141 [52,176,177] and circ_0081234 [157]	
Distinguish treatment-naïve PCa from CRPC	/	miR-423-3p [183]	/	
Distinguish PCa with different GS	miR-145 [173], PCA3 [178] and MALAT1 [178]	let-7a-5p [53]	/	
Identify metastatic PCa after radical prostatectomy	/	/	miR-141 [52,176,177], miR-375 [177] and miR-1246 [98]	
Prognostic biomarkers	Associated with poor overall survival	/	miR-375 [184] and miR-1290 [184]	/	
Abbreviation: PCa, prostate cancer; CRPC, castration-resistant prostate cancer; GS, Gleason Score; SM, spine metastasis; HS, healthy subjects; BPH, benign prostatic hyperplasia.

4.1 Exosomal ncRNAs as diagnostic biomarkers

Exosomal ncRNAs represent reliable and precise biomarkers for PCa diagnosis. At present, PSA screening is the first choice for all patients due to its efficiency. However, it also leads to overdiagnosis and overtreatment because it is prostate-specific, not PCa-specific [10]. Other diagnostic methods, such as tissue biopsy, imaging examination and digital rectal examination (DRE), are not routinely recommended for newly admitted patients because of their limitations, such as invasiveness, high cost, and poor diagnostic performance [167,168]. Exosomes have become a research hotspot and provide a promising alternative to liquid biopsy with better overall diagnostic performance [169]. Particularly, ncRNAs in exosomes are important modulators and biomarkers. Therefore, exosomal ncRNAs may offer a new and valuable choice for PCa diagnosis.

The focus of numerous research has been on exosomal miRNAs as biomarkers for diagnosing PCa. For example, the levels of miR-196a-5p [170], miR-501-3p [170], miR-375 [171] and miR-19b [172] are significantly decreased in urinary exosomes from patients with PCa in comparison to those from non-cancerous subjects. Conversely, the expression levels of miR-451a [171], miR-486-3p [171], miR-486-5p [171], miR-21 [51,52], miR-375 [51], let-7c [51], miR-141-5p [52], miR-574-3p [52], miR-145 [173], miR-1290 [173] and miR-2909 [174] are significantly higher in urinary exosomes from patients with PCa in comparison to those from non-cancerous subjects. In exosomes from plasma, miR-200c-3p [53], miR-21-5p [53] and miR-141-5p [175] are significantly overexpressed and utilized to differentiate between patients with PCa and non-cancerous subjects. Additionally, the decline of miR-125a-5p in plasma exosomes is valuable for diagnosing PCa patients and healthy subjects [175]. Similarly, in exosomes from serum, miR-212 is significantly downregulated [150], whereas miR-141 is significantly upregulated [52,176,177], which is meaningful in PCa diagnosis. Moreover, combining multiple biomarkers, including miR-375, miR-451a, miR-486-3p and miR-486-5p [171], miR-21 and miR-375 [51], miR-125a-5p and miR-141-5p [175], PCA3 and MALAT1 [178], or SChLAP1 and SAP30L-AS1 [179], can increase the diagnostic accuracy.

As a part of ncRNAs, exosomal lncRNAs are also valuable diagnostic biomarkers in PCa. Specific exosomal lncRNAs are enriched or decreased and contain miRNA seeds or RNA-binding protein binding (RBP) motifs [180], which make lncRNAs valuable diagnostic biomarkers. In urinary exosomes, PCA3 [178], MALAT1 [178] and lncRNA-p21 [181] are significantly upregulated and serve for PCa diagnosis. The diagnostic performance of exosomal PCA3 and MALAT1 in combination is superior to that of PCA3 or MALAT1 alone. Moreover, the diagnostic performance is further enhanced by combining urinary exosomal PCA3 and MALAT1, PSA, fPSA/tPSA, and a model that includes age, prostate volume, and DRE status [178]. Similarly, serum exosomes from patients with PCa show significant upregulation of SChLAP1 [179] and lncAY927529 [139], compared to those from normal volunteers.

Exosomal circRNAs can also function for PCa diagnosis. Specifically, exosomal circ_0044516 is increased in the serum of patients with PCa and differentiates them from normal subjects [154]. Similarly, exosomal circHIPK3 is also a diagnostic biomarker found in serum and it is meaningfully increased in patients with PCa in comparison to normal subjects [150]. Both circ_0044516 and circHIPK3 act as miRNA sponges and bind to miR-212 and miR-330-5p, respectively [150,182]. This may explain the decline of miR-212 and miR-330-5p in the exosomes.

4.2 Exosomal ncRNAs as staging and grading biomarkers

In addition to diagnosing PCa, exosomal ncRNAs also function as staging and grading biomarkers. Understanding the stage and grade of PCa is essential as it reveals the current status of the disease and the degree of malignancy. This information can help clinicians make informed therapeutic decisions.

Different PCa stages affect the choice of therapy, making it necessary to determine the disease stage. According to studies, patients with metastatic PCa exhibit overexpression of miR-1290 and decreased levels of miR-375 in urinary exosomes as compared to those with localized PCa [171,173]. Furthermore, overexpression of exosomal miR-141 [176] and miR-1246 [98] in serum can distinguish whether PCa metastasizes or not like miR-1290. Additionally, serum exosomal circ_0081234 is meaningfully overexpressed in patients with PCa SM, suggesting its utility for PCa staging [157]. Plasma exosomal miR-423-3p is meaningfully increased in patients with CRPC than in those with non-CRPC [183]. Additionally, after undergoing radical prostatectomy, serum exosomal miR-375 and miR-141 are meaningfully increased in patients with metastatic PCa compared to those without relapse [177].

The GS of PCa is associated with treatment decisions and risk stratification. Exosomal ncRNAs can help determine GS values. For example, overexpression of urinary exosomal miR-145 can be used to significantly determine GS ≥ 8 or GS ≤ 7 in patients with PCa [173]. Conversely, the decline of plasma exosomal let-7a-5p is meaningful when distinguishing GS ≥ 8 or GS ≤ 6 in patients with PCa [53]. PCA3 and MALAT1 are also associated with GS. The levels of these biomarkers are significantly upregulated in urinary exosomes and utilized to distinguish patients with PCa with a high GS (GS ≥ 7) from those with other non-aggressive diseases (PCa with a GS ≤ 6 and benign disease) [178]. By quantifying these ncRNAs, clinicians can determine the stage and grade of patients without invasive biopsies.

4.3 Exosomal ncRNAs as prognostic biomarkers

Exosomal ncRNAs are also useful for predicting patient survival. For example, patients with CRPC after ADT failure show significant upregulation of plasma exosomal miR-1290 and miR-375, indicating their potential for survival prediction. Moreover, the predictive performance of the prognosis is significantly improved by measuring the ratio of miR-1290/miR-375 [184]. Similarly, circ_14736 and circ_17720 form a part of the circRNA signature model. This model, including eight circRNAs, predicted the biochemical recurrence of PCa [185]. These findings suggest that exosomal ncRNAs have prognostic value and can be used to develop effective predictive models for patients with PCa.

5 Clinical application of exosomal ncRNAs

5.1 Exosomal ncRNAs as biomarkers

Given the roles of exosomal ncRNAs as modulators and biomarkers, they hold promise as novel biomarkers in clinical settings. Based on the apparent differences in exosomal ncRNAs between patients with PCa and others, some studies have used them to diagnose. Wei et al. [186] and Wang et al. [187] designed diverse techniques for the ultrasensitive detection of miR-141. Additionally, Kim et al. [188] successfully measured urinary exosomal miR-6090 and miR-3665 levels in patients with PCa, developed a dual amplification approach, and identified its potential in PCa diagnosis. Moreover, by targeting exosomal miR-21 and surface CD63, Cho et al. [189] could determine whether exosomes derived from cancerous prostate cells or not. The sequence between two lncRNAs or circRNAs has some repeat sites, leading to low efficiency in constructing a system to detect specific sequences of lncRNAs or circRNAs. Hence, real-time fluorescence polymerase chain reaction (PCR) and other methods are commonly used to directly measure the expression of lncRNAs or circRNAs.

Although significant progress has been made in detecting specific biomarkers in the plasma, serum or exosomes, the time-consuming procedures and high technical requirements of some methods make biosensing through exosomal ncRNAs non-mainstream. However, the high enrichment of ncRNAs in exosomes makes it easier to collect the same type of ncRNAs and send signals without acquiring a large volume of body liquid. In addition, some researchers have successfully applied their detection assays from basic research to clinical applications with high diagnostic efficiency [187,188], showing that exosomal ncRNAs have excellent detection performance in PCa. These detection systems not only show compatibility with PCR but also have higher specificity than typical PSA tests.

It is critical to standardize the collection and measurement of exosomal ncRNAs before accurately understanding the relationship between ncRNAs and PCa. Several highly sensitive and specific assays have been developed to determine exosomal miRNAs related to PCa. However, the absence of standardization in the collection and measurement of miRNAs can lead to different conclusions. For instance, Foj et al. [51] found that urinary exosomal miR-141 exhibits no apparent difference in diagnosing PCa upon using differential centrifugation, which differs when comparing urinary exosomal miR-141 by lectin-based exosome agglutination method [52]. Additionally, other potential factors should be explored, such as prostate massage, urine volume, urine concentration, renal function and hemodynamic status [14].

5.2 Exosomal ncRNAs as potential therapeutic tools

Besides as biomarkers, exosomal ncRNAs are hopeful targets for cancer therapy. The ncRNAs encased in exosomes are biocompatible and more prone to evade attacks by the immune system. Exosomal ncRNAs are more stable than ncRNAs in bodily fluids and can cross physiological barriers, because of their biocompatibility. Specific miRNAs in endogenous exosomes derived from stem cells can protect adjacent cells [190,191]. Exogenous ncRNAs can be incorporated into synthetic exosomes using methods like electroporation, lipofection, sonication or calcium chloride treatment [192]. Synthetic exosomes can induce gene silencing with loaded ncRNAs, leading to the knockdown of cancer oncogenes [193,194]. Furthermore, exosomal ncRNAs have been used to breast cancer [195], ovarian cancer [196], osteosarcoma [197], colorectal cancer [198] and other cancers (Table 3). Overall, loading ncRNAs into exosomes is promising for PCa.Table 3 The therapeutic potential of exosomal ncRNAs.

Table 3ncRNAs	Carrier	Target	Model	Role	Reference	
let-7a	Modified exosomes	EGFR-expressing breast cancer	In vivo and in vitro	Inhibited tumor growth	[195]	
miR-497	Hybrid nanoparticles of liposomes and exosomes	Ovarian cancer	In vivo and in vitro	Led to tumor cell death and overcame drug resistance	[196]	
anti-miR-21	Anti-exosome antibody–oligonucleotide complexes	Exosome	In vitro	Inhibited exosomal miR-21 to prohibit cancer cell growth	[199]	
lncRNA MEG3	Modified exosomes	Osteosarcoma	In vivo and in vitro	Inhibited proliferation, migration and promoted apoptosis by regulating miR-185-5p	[197]	
ciRS-122	Exosome	Colorectal cancer	In vivo and in vitro	Suppressed glycolysis and reversed resistance to oxaliplatin by regulating the ciRS-122-miR-122-PKM2 pathway	[198]	

6 Conclusions

According to published studies, exosomal ncRNAs have emerged as key regulators of multiple signaling pathways, critically influencing PCa initiation, growth, progression and therapy resistance. The relationship among exosomal ncRNAs, signaling pathways and cellular activities is complex and requires further exploration. Understanding the involvement of exosomal ncRNAs in tumorigenesis, progression and therapeutic response will usher in a new era in PCa diagnosis and treatment. Given their predictive effects in PCa, exosomal ncRNAs can function as innovative biomarkers and construct a professional system that can identify, classify, monitor PCa, predict patient survival, and assist in medical decision-making. Additionally, new therapeutic methods may target exosomal ncRNAs to intervene in oncogene expression, and exosomes can be designed to transport functional ncRNAs to cancer cells. However, the lack of a recognized protocol for obtaining exosomes remains a challenge and researchers must collaborate to determine the best separation and detection techniques based on stability, accuracy and selectivity to facilitate credible research results. Furthermore, exosomal ncRNA expression in various body fluids of patients with PCa at each stage requires reliable average measurements through multiple assessments. With the combined efforts of researchers, exosomal ncRNAs in PCa will be better explored and successfully applied in clinical practice.

Funding

This study was supported by the 10.13039/501100001809 National Natural Science Foundation of China (82122042 ), Chongqing Science Fund for Distinguished Young Scholars (CSTB2022NSCQ-JQX0007 ), Chongqing Medical Scientific Research Project (2023ZDXM021 ) and Key Project for Clinical Innovation of 10.13039/501100012397 Army Medical University (CX2019LC107 ).

CRediT authorship contribution statement

Yongxing Li: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Xiaoqi Tang: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Binpan Wang: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Ming Chen: Writing – review & editing, Supervision. Ji Zheng: Writing – review & editing, Supervision, Funding acquisition. Kai Chang: Writing – review & editing, Supervision, Funding acquisition.

Declaration of competing interest

There are no conflicts of interest to declare.
==== Refs
References

1 Siegel R.L. Miller K.D. Fuchs H.E. Jemal A. Cancer statistics Ca-Cancer J. Clin. 72 1 2022 7 33 10.3322/caac.21708 35020204
2 Xia C. Dong X. Li H. Cancer statistics in China and United States, 2022: profiles, trends, and determinants Chinese Med J 135 5 2022 584 590 10.1097/CM9.0000000000002108
3 Pulliam T.L. Goli P. Awad D. Regulation and role of CAMKK2 in prostate cancer Nat. Rev. Urol. 19 6 2022 367 380 10.1038/s41585-022-00588-z 35474107
4 Foreman K.J. Marquez N. Dolgert A. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories Lancet 392 10159 2018 2052 2090 10.1016/S0140-6736(18)31694-5 30340847
5 Arenas-Gallo C. Owiredu J. Weinstein I. Race and prostate cancer: genomic landscape Nat. Rev. Urol. 19 9 2022 547 561 10.1038/s41585-022-00622-0 35945369
6 Van Poppel H. Albreht T. Basu P. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future Nat. Rev. Urol. 19 9 2022 562 572 10.1038/s41585-022-00638-6 35974245
7 Sandhu S. Moore C.M. Chiong E. Prostate cancer Lancet 398 10305 2021 1075 1090 10.1016/S0140-6736(21)00950-8 34370973
8 Disease G.B.D. Incidence Injury and Collaborators Prevalence, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 10159 2018 1789 1858 10.1016/S0140-6736(18)32279-7 30496104
9 Pinsky P.F. Black A. Daugherty S.E. Metastatic prostate cancer at diagnosis and through progression in the prostate, lung, colorectal, and ovarian cancer screening trial Cancer 125 17 2019 2965 2974 10.1002/cncr.32176 31067347
10 Mistry Kishor Cable Greg Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma J. Am. Board Fam. Pract. 16 2 2003 95 101 12665174
11 Zhang L. Yu D. Exosomes in cancer development, metastasis, and immunity Biochim. Biophys. Acta Rev. Canc 1871 2 2019 455 468 10.1016/j.bbcan.2019.04.004
12 Filella X. Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers Int. J. Mol. Sci. 17 11 2016 10.3390/ijms17111784
13 Tang X. Wang Y. Zhou L. Strand displacement-triggered G-quadruplex/rolling circle amplification strategy for the ultra-sensitive electrochemical sensing of exosomal microRNAs Mikrochim. Acta 187 3 2020 172 10.1007/s00604-020-4143-9 32062754
14 Wang Jingpu Ni Jie Beretov Julia Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer Crit. Rev. Oncol. Hematol. 145 2020 102860 10.1016/j.critrevonc.2019.102860
15 Sun Z. Shi K. Yang S. Effect of exosomal miRNA on cancer biology and clinical applications Mol. Cancer 17 1 2018 147 10.1186/s12943-018-0897-7 30309355
16 Sun Z. Yang S. Zhou Q. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment Mol. Cancer 17 1 2018 82 10.1186/s12943-018-0831-z 29678180
17 Wang Y. Liu J. Ma J. Exosomal circRNAs: biogenesis, effect and application in human diseases Mol. Cancer 18 1 2019 116 10.1186/s12943-019-1041-z 31277663
18 Ali A. Du Feu A. Oliveira P. Prostate zones and cancer: lost in transition? Nat. Rev. Urol. 19 2 2022 101 115 10.1038/s41585-021-00524-7 34667303
19 Baures M. Dariane C. Tika E. Prostate luminal progenitor cells: from mouse to human, from health to disease Nat. Rev. Urol. 19 4 2022 201 218 10.1038/s41585-021-00561-2 35079142
20 Teng F. Fussenegger M. Shedding light on extracellular vesicle biogenesis and bioengineering Adv. Sci. 8 1 2020 2003505 10.1002/advs.202003505
21 Thakur A. Parra D.C. Motallebnejad P. Brocchi M. Chen H.J. Exosomes: small vesicles with big roles in cancer, vaccine development, and therapeutics Bioact. Mater. 2022 10.1016/j.bioactmat.2021.08.029
22 Kalluri R. LeBleu V.S. The biology, function, and biomedical applications of exosomes Science 367 6478 2020 10.1126/science.aau6977
23 Mathivanan S. Fahner C.J. Reid G.E. Simpson R.J. ExoCarta 2012: database of exosomal proteins, RNA and lipids Nucleic Acids Res. 40 Database issue 2012 D1241 D1244 10.1093/nar/gkr828 21989406
24 Vlaeminck-Guillem V. Extracellular vesicles in prostate cancer carcinogenesis, diagnosis, and management Front. Oncol. 8 2018 222 10.3389/fonc.2018.00222 29951375
25 Fedele C. Singh A. Zerlanko B.J. Iozzo R.V. Languino L.R. The alphavbeta6 integrin is transferred intercellularly via exosomes J. Biol. Chem. 290 8 2015 4545 4551 10.1074/jbc.C114.617662 25568317
26 Brzozowski J.S. Bond D.R. Jankowski H. Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion Sci. Rep. 8 1 2018 8822 10.1038/s41598-018-27180-z 29891991
27 Mashouri L. Yousefi H. Aref A.R. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance Mol. Cancer 18 1 2019 75 10.1186/s12943-019-0991-5 30940145
28 Vinik Yaron Ortega Francisco Gabriel Mills Gordon B. Proteomic analysis of circulating extracellular vesicles Sci. Adv. 6 2020
29 Llorente A. Skotland T. Sylvanne T. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells Biochim. Biophys. Acta 1831 7 2013 1302 1309 10.1016/j.bbalip.2013.04.011 24046871
30 Luo X. Zhao X. Cheng C. The implications of signaling lipids in cancer metastasis Exp. Mol. Med. 50 9 2018 1 10 10.1038/s12276-018-0150-x
31 Cheng L. Zhang K. Qing Y. Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells J. Ovarian Res. 13 1 2020 9 10.1186/s13048-020-0609-y 31969186
32 Tao L. Zhou J. Yuan C. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer Metabolomics 15 6 2019 86 10.1007/s11306-019-1550-1 31147790
33 Zhang H. Freitas D. Kim H.S. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation Nat. Cell Biol. 20 3 2018 332 343 10.1038/s41556-018-0040-4 29459780
34 Wang J. Zhu S. Meng N. ncRNA-encoded peptides or proteins and cancer Mol. Ther. 27 10 2019 1718 1725 10.1016/j.ymthe.2019.09.001 31526596
35 Anastasiadou E. Jacob L.S. Slack F.J. Non-coding RNA networks in cancer Nat. Rev. Cancer 18 1 2018 5 18 10.1038/nrc.2017.99 29170536
36 Bullock M.D. Silva A.M. Kanlikilicer-Unaldi P. Exosomal non-coding RNAs: diagnostic, prognostic and therapeutic applications in cancer Noncoding RNA 1 1 2015 53 68 10.3390/ncrna1010053 29861415
37 Wei Z. Batagov A.O. Schinelli S. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells Nat. Commun. 8 1 2017 1145 10.1038/s41467-017-01196-x 29074968
38 Slack F.J. Chinnaiyan A.M. The role of non-coding RNAs in oncology Cell 179 5 2019 1033 1055 10.1016/j.cell.2019.10.017 31730848
39 Su M. Xiao Y. Ma J. Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers Mol. Cancer 18 1 2019 90 10.1186/s12943-019-1002-6 30999909
40 Jeck W.R. Sorrentino J.A. Wang K. Circular RNAs are abundant, conserved, and associated with ALU repeats RNA 19 2 2013 141 157 10.1261/rna.035667.112 23249747
41 Li Y. Zheng Q. Bao C. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis Cell Res. 25 8 2015 981 984 10.1038/cr.2015.82 26138677
42 Tang X.H. Guo T. Gao X.Y. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications Mol. Cancer 20 1 2021 99 10.1186/s12943-021-01396-6 34330299
43 Hanahan D. Hallmarks of cancer: new dimensions Cancer Discov. 12 1 2022 31 46 10.1158/2159-8290.CD-21-1059 35022204
44 Hanahan D. Weinberg R.A. Hallmarks of cancer: the next generation Cell 144 5 2011 646 674 10.1016/j.cell.2011.02.013 21376230
45 Hanahan D. Weinberg R.A. The hallmarks of cancer Cell 100 1 2000 57 70 10.1016/s0092-8674(00)81683-9 10647931
46 Aslan C. Maralbashi S. Salari F. Tumor-derived exosomes: implication in angiogenesis and antiangiogenesis cancer therapy J. Cell. Physiol. 234 10 2019 16885 16903 10.1002/jcp.28374 30793767
47 Olejarz W. Kubiak-Tomaszewska G. Chrzanowska A. Lorenc T. Exosomes in angiogenesis and anti-angiogenic therapy in cancers Int. J. Mol. Sci. 21 16 2020 10.3390/ijms21165840
48 Prigol A.N. Rode M.P. Silva A.H. Cisilotto J. Creczynski-Pasa T.B. Pro-angiogenic effect of PC-3 exosomes in endothelial cells in vitro Cell. Signal. 87 2021 110126 10.1016/j.cellsig.2021.110126
49 Arroyo A B. Salloum-Asfar S. Perez-Sanchez C. Regulation of TFPIalpha expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens Sci. Rep. 7 1 2017 43500 10.1038/srep43500
50 Holroyd E.W. Delacroix S. Larsen K. Tissue factor pathway inhibitor blocks angiogenesis via its carboxyl terminus Arterioscler. Thromb. Vasc. Biol. 32 3 2012 704 711 10.1161/ATVBAHA.111.243733 22223730
51 Foj L. Ferrer F. Serra M. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis Prostate 77 6 2017 573 583 10.1002/pros.23295 27990656
52 Samsonov R. Shtam T. Burdakov V. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic Prostate 76 1 2016 68 79 10.1002/pros.23101 26417675
53 Endzelins E. Berger A. Melne V. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients BMC Cancer 17 1 2017 730 10.1186/s12885-017-3737-z 29121858
54 Liu L.Z. Li C. Chen Q. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression PLoS One 6 4 2011 e19139 10.1371/journal.pone.0019139
55 Costanzi E. Romani R. Scarpelli P. Bellezza I. Extracellular vesicles-mediated transfer of miRNA let-7b from PC3 cells to macrophages Genes 11 12 2020 10.3390/genes11121495
56 Chen Z. Lai T.C. Jan Y.H. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis J. Clin. Invest. 123 3 2013 1057 1067 10.1172/JCI65344 23426184
57 Zhu Y. Zhang J. Hu X. Extracellular vesicles derived from human adipose-derived stem cells promote the exogenous angiogenesis of fat grafts via the let-7/AGO1/VEGF signalling pathway Sci. Rep. 10 1 2020 5313 10.1038/s41598-020-62140-6 32210269
58 Shang A. Gu C. Wang W. Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-beta1 axis Mol. Cancer 19 1 2020 117 10.1186/s12943-020-01235-0 32713345
59 Zheng P. Chen L. Yuan X. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells J. Exp. Clin. Cancer Res. 36 1 2017 53 10.1186/s13046-017-0528-y 28407783
60 Au Yeung C.L. Co N.N. Tsuruga T. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 Nat. Commun. 7 2016 11150 10.1038/ncomms11150
61 Jiang S. Chen H. He K. Wang J. Human bone marrow mesenchymal stem cells-derived exosomes attenuated prostate cancer progression via the miR-99b-5p/IGF1R axis Bioengineered 13 2 2022 2004 2016 10.1080/21655979.2021.2009416 35030978
62 Lang C. Yin C. Lin K. m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization Clin. Transl. Med. 11 6 2021 e426 10.1002/ctm2.426 34185427
63 Ding Y. Wang M. Yang J. Circular RNA midline-1 (circMID1) promotes proliferation, migration, invasion and glycolysis in prostate cancer Bioengineered 13 3 2022 6293 6308 10.1080/21655979.2022.2037367 35212614
64 Heidegger Isabel Kern Johann Ofer Philipp Klocker Helmut Massoner Petra Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis Oncotarget 5 9 2014 2723 2735 24809298
65 Dai Y. Gao X. Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1 Cancer Cell Int. 21 1 2021 145 10.1186/s12935-020-01686-x 33653339
66 Wang R. Xiao Y. Pan M. Chen Z. Yang P. Integrative analysis of bulk RNA-Seq and single-cell RNA-Seq unveils the characteristics of the immune microenvironment and prognosis signature in prostate cancer J. Oncol. 2022 2022 6768139 10.1155/2022/6768139
67 Li T. Li D. Sha J. Sun P. Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells Biochem. Biophys. Res. Commun. 383 3 2009 280 285 10.1016/j.bbrc.2009.03.077 19302977
68 Zhang W. Li W. Han X. Skullcapflavone I inhibits proliferation of human colorectal cancer cells via down-regulation of miR-107 expression Neoplasma 66 2 2019 203 210 10.4149/neo_2018_180427N279 30509103
69 Jiang R. Zhang C. Liu G. Gu R. Wu H. MicroRNA-107 promotes proliferation, migration, and invasion of osteosarcoma cells by targeting tropomyosin 1 Oncol. Res. 25 8 2017 1409 1419 10.3727/096504017X14882829077237 28276320
70 Zhou C. Chen Y. He X. Zheng Z. Xue D. Functional implication of exosomal miR-217 and miR-23b-3p in the progression of prostate cancer OncoTargets Ther. 13 2020 11595 11606 10.2147/OTT.S272869
71 Lin H.M. Nikolic I. Yang J. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer Sci. Rep. 8 1 2018 7820 10.1038/s41598-018-26050-y 29777112
72 Zhang Z. Chen L. Wang H. Ahmad N. Liu X. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer Cell Cycle 14 13 2015 2142 2148 10.1080/15384101.2015.1041689 25927139
73 Sulzmaier F.J. Jean C. Schlaepfer D.D. FAK in cancer: mechanistic findings and clinical applications Nat. Rev. Cancer 14 9 2014 598 610 10.1038/nrc3792 25098269
74 Jiang S. Mo C. Guo S. Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the progression of prostate cancer through suppression of RHPN2 J. Exp. Clin. Cancer Res. 38 1 2019 495 10.1186/s13046-019-1488-1 31847864
75 Peck J.W. Oberst M. Bouker K.B. Bowden E. Burbelo P.D. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization J. Biol. Chem. 277 46 2002 43924 43932 10.1074/jbc.M203569200 12221077
76 Hu W.Y. Afradiasbagharani P. Lu R. Morphometric analysis of rat prostate development: roles of MEK/ERK and Rho signaling pathways in prostatic morphogenesis Biomolecules 11 12 2021 10.3390/biom11121829
77 Guan H. Peng R. Fang F. Tumor-associated macrophages promote prostate cancer progression via exosome-mediated miR-95 transfer J. Cell. Physiol. 235 12 2020 9729 9742 10.1002/jcp.29784 32406953
78 Thomsen M.K. Bakiri L. Hasenfuss S.C. Loss of JUNB/AP-1 promotes invasive prostate cancer Cell Death Differ. 22 4 2015 574 582 10.1038/cdd.2014.213 25526087
79 Birner P. Egger G. Merkel O. Kenner L. JunB and PTEN in prostate cancer: 'loss is nothing else than change' Cell Death Differ. 22 4 2015 522 523 10.1038/cdd.2014.232 25747853
80 Liu Q. Zhang H. Jiang X. Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis Mol. Cancer 16 1 2017 176 10.1186/s12943-017-0742-4 29197379
81 Wu Q. Zhou L. Lv D. Zhu X. Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression J. Hematol. Oncol. 12 1 2019 53 10.1186/s13045-019-0739-0 31142326
82 Sung B.H. Parent C.A. Weaver A.M. Extracellular vesicles: critical players during cell migration Dev. Cell 56 13 2021 1861 1874 10.1016/j.devcel.2021.03.020 33811804
83 Pardo F. Villalobos-Labra R. Sobrevia B. Toledo F. Sobrevia L. Extracellular vesicles in obesity and diabetes mellitus Mol. Aspect. Med. 60 2018 81 91 10.1016/j.mam.2017.11.010
84 Yang E. Wang X. Gong Z. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression Signal Transduct. Targeted Ther. 5 1 2020 242 10.1038/s41392-020-00359-5
85 Bertoli G. Panio A. Cava C. Secreted miR-153 controls proliferation and invasion of higher Gleason score prostate cancer Int. J. Mol. Sci. 23 11 2022 10.3390/ijms23116339
86 Ma J.B. Bai J.Y. Zhang H.B. KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1 Cell Death Dis. 11 6 2020 466 10.1038/s41419-020-2671-1 32546700
87 Nan C. Wang Y. Yang S. Chen Y. circCRKL suppresses the progression of prostate cancer cells by regulating the miR-141/KLF5 axis Pathol. Res. Pract. 216 11 2020 153182 10.1016/j.prp.2020.153182
88 Hasegawa T. Glavich G.J. Pahuski M. Characterization and evidence of the miR-888 cluster as a novel cancer network in prostate Mol. Cancer Res. 16 4 2018 669 681 10.1158/1541-7786.MCR-17-0321 29330297
89 Tonini T. D'Andrilli G. Fucito A. Gaspa L. Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements J. Cell. Physiol. 214 2 2008 295 300 10.1002/jcp.21241 17786943
90 Wang K. Chen Z. Shi J. Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells Prostate 80 12 2020 977 985 10.1002/pros.24029 32542727
91 Jeong J.W. Jin C.Y. Park C. Inhibition of migration and invasion of LNCaP human prostate carcinoma cells by cordycepin through inactivation of Akt Int. J. Oncol. 40 5 2012 1697 1704 10.3892/ijo.2012.1332 22246470
92 Ding Z. Wu C.J. Chu G.C. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression Nature 470 7333 2011 269 273 10.1038/nature09677 21289624
93 Wa Q. Li L. Lin H. Downregulation of miR-19a-3p promotes invasion, migration and bone metastasis via activating TGF-beta signaling in prostate cancer Oncol. Rep. 39 1 2018 81 90 10.3892/or.2017.6096 29138858
94 Zhang Y. Zhao J. Ding M. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis J. Exp. Clin. Cancer Res. 39 1 2020 282 10.1186/s13046-020-01761-1 33317606
95 Zhang H. Liang F. Yue J. MicroRNA-137 regulates hypoxia-mediated migration and epithelial-mesenchymal transition in prostate cancer by targeting LGR4 via the EGFR/ERK signaling pathway Int. J. Oncol. 57 2 2020 540 549 10.3892/ijo.2020.5064 32626928
96 Peraldo-Neia C. Migliardi G. Mello-Grand M. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer BMC Cancer 11 2011 31 10.1186/1471-2407-11-31 21266046
97 Mittal V. Epithelial mesenchymal transition in tumor metastasis Annu. Rev. Pathol. 13 2018 395 412 10.1146/annurev-pathol-020117-043854 29414248
98 Bhagirath D. Yang T.L. Bucay N. microRNA-1246 is an exosomal biomarker for aggressive prostate cancer Cancer Res. 78 7 2018 1833 1844 10.1158/0008-5472.CAN-17-2069 29437039
99 Wang X. Wang X. Zhu Z. Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma Biomed. Pharmacother. 117 2019 109109 10.1016/j.biopha.2019.109109
100 Kato M. Goto Y. Matsushita R. MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer Int. J. Oncol. 47 2 2015 710 718 10.3892/ijo.2015.3043 26063484
101 Abd Elmageed Z.Y. Yang Y. Thomas R. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes Stem Cell. 32 4 2014 983 997 10.1002/stem.1619
102 Guo Y. Cui J. Ji Z. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance Oncogene 36 45 2017 6336 6347 10.1038/onc.2017.240 28745315
103 Sheth S. Jajoo S. Kaur T. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway PLoS One 7 12 2012 e51655 10.1371/journal.pone.0051655
104 Albino D. Falcione M. Uboldi V. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer Commun. Biol. 4 1 2021 119 10.1038/s42003-020-01642-5 33500545
105 Dallavalle C. Albino D. Civenni G. MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression J. Clin. Invest. 126 12 2016 4585 4602 10.1172/JCI86505 27820701
106 Mezzasoma L. Costanzi E. Scarpelli P. Talesa V.N. Bellezza I. Extracellular vesicles from human advanced-stage prostate cancer cells modify the inflammatory response of microenvironment-residing cells Cancers 11 9 2019 10.3390/cancers11091276
107 Rong J. Xu L. Hu Y. Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1/STAT pathway in prostate cancer Cancer Cell Int. 20 2020 470 10.1186/s12935-020-01563-7 33005103
108 Ye Y. Li S.L. Ma Y.Y. Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer Oncotarget 8 55 2017 94834 94849 10.18632/oncotarget.22014 29212270
109 Tripathi V. Popescu N.C. Zimonjic D.B. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion Oncogene 33 6 2014 724 733 10.1038/onc.2013.7 23376848
110 Li S.L. An N. Liu B. Exosomes from LNCaP cells promote osteoblast activity through miR-375 transfer Oncol. Lett. 17 5 2019 4463 4473 10.3892/ol.2019.10110 30988815
111 Lei N.B. Liang X. Wang P. Liu Q. Wang W.G. Teriparatide alleviates osteoporosis by promoting osteogenic differentiation of hMSCs via miR-375/RUNX2 axis Eur. Rev. Med. Pharmacol. Sci. 23 24 2019 11043 11050 10.26355/eurrev_201912_19812 31858576
112 Baniwal S.K. Khalid O. Gabet Y. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis Mol. Cancer 9 1 2010 258 10.1186/1476-4598-9-258 20863401
113 Hashimoto K. Ochi H. Sunamura S. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A Proc. Natl. Acad. Sci. U.S.A. 115 9 2018 2204 2209 10.1073/pnas.1717363115 29440427
114 Rowena McBeath Pirone Dana M. Nelson Celeste M. Bhadriraju Kiran Chen Christopher S. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment Dev. Cell 6 4 2004 483 495 15068789
115 Clay M.R. Halloran M.C. Rho activation is apically restricted by Arhgap1 in neural crest cells and drives epithelial-to-mesenchymal transition Development 140 15 2013 3198 3209 10.1242/dev.095448 23804498
116 Zou Z. Dai R. Deng N. Su W. Liu P. Exosomal miR-1275 secreted by prostate cancer cells modulates osteoblast proliferation and activity by targeting the SIRT2/RUNX2 cascade Cell Transplant. 30 2021 9636897211052977 10.1177/09636897211052977
117 Furesi G. de Jesus Domingues A.M. Alexopoulou D. Exosomal miRNAs from prostate cancer impair osteoblast function in mice Int. J. Mol. Sci. 23 3 2022 10.3390/ijms23031285
118 Graham T.R. Odero-Marah V.A. Chung L.W. PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells Prostate 69 2 2009 168 180 10.1002/pros.20870 18942118
119 Yu L. Sui B. Fan W. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p J. Extracell. Vesicles 10 3 2021 e12056 10.1002/jev2.12056
120 Rodriguez-Nieves J.A. Patalano S.C. Almanza D. Gharaee-Kermani M. Macoska J.A. CXCL12/CXCR4 Axis activation mediates prostate myofibroblast phenoconversion through non-canonical EGFR/MEK/ERK signaling PLoS One 11 7 2016 e0159490 10.1371/journal.pone.0159490
121 El-Sayed I.Y. Daher A. Destouches D. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling Cancer Lett. 410 2017 100 111 10.1016/j.canlet.2017.09.010 28935391
122 Lin P.C. Chiu Y.L. Banerjee S. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression Cancer Res. 73 3 2013 1232 1244 10.1158/0008-5472.CAN-12-2968 23233736
123 Bhatnagar N. Li X. Padi S.K. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells Cell Death Dis. 1 12 2010 e105 10.1038/cddis.2010.85 21368878
124 Ribas J. Ni X. Haffner M. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth Cancer Res. 69 18 2009 7165 7169 10.1158/0008-5472.CAN-09-1448 19738047
125 Coradduzza D. Cruciani S. Arru C. Role of miRNA-145, 148, and 185 and stem cells in prostate cancer Int. J. Mol. Sci. 23 3 2022 10.3390/ijms23031626
126 He J.H. Zhang J.Z. Han Z.P. Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells J. Exp. Clin. Cancer Res. 33 1 2014 72 10.1186/s13046-014-0072-y 25200485
127 Cao Z. Xu L. Zhao S. Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate cancer chemoresistance through p53 Biochem. Biophys. Res. Commun. 515 2 2019 345 351 10.1016/j.bbrc.2019.05.120 31153637
128 Chappell W.H. Candido S. Abrams S.L. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines Aging (Albany NY) 12 11 2020 10194 10210 10.18632/aging.103377 32492656
129 Pascal L.E. Wang Y. Zhong M. EAF2 and p53 Co-regulate STAT3 activation in prostate cancer Neoplasia 20 4 2018 351 363 10.1016/j.neo.2018.01.011 29518696
130 Shan G. Gu J. Zhou D. Cancer-associated fibroblast-secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-beta signaling pathway Exp. Mol. Med. 52 11 2020 1809 1822 10.1038/s12276-020-0431-z 33144675
131 Corcoran C. Rani S. O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression Prostate 74 13 2014 1320 1334 10.1002/pros.22848 25053345
132 Li Y. Zhang B. Xiang L. TGF-Beta causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization Theranostics 10 17 2020 7656 7670 10.7150/thno.44567 32685011
133 Tang C. Liu T. Wang K. Transcriptional regulation of FoxM1 by HIF-1alpha mediates hypoxia-induced EMT in prostate cancer Oncol. Rep. 42 4 2019 1307 1318 10.3892/or.2019.7248 31364741
134 Kim J.H. Lee H. Shin E.A. Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression Expert Opin. Ther. Targets 21 9 2017 911 920 10.1080/14728222.2017.1369044 28816549
135 Wang J. Yang X. Li R. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis Oncol. Rep. 40 5 2018 2814 2825 10.3892/or.2018.6661 30132573
136 Rebello R.J. Pearson R.B. Hannan R.D. Furic L. Therapeutic approaches targeting MYC-driven prostate cancer Genes 8 2 2017 71 10.3390/genes8020071 28212321
137 Ge J. Yu W. Li J. USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc J. Exp. Clin. Cancer Res. 40 1 2021 59 10.1186/s13046-021-01843-8 33546726
138 Ding T. Zhu Y. Jin H. Circular RNA circ_0057558 controls prostate cancer cell proliferation through regulating miR-206/USP33/c-Myc Axis Front. Cell Dev. Biol. 9 2021 644397 10.3389/fcell.2021.644397
139 Li Q. Hu J. Shi Y. Exosomal lncAY927529 enhances prostate cancer cell proliferation and invasion through regulating bone microenvironment Cell Cycle 20 23 2021 2531 2546 10.1080/15384101.2021.1992853 34724861
140 Tian H.Y. Liang Q. Shi Z. Zhao H. Exosomal CXCL14 contributes to M2 macrophage polarization through NF-kappaB signaling in prostate cancer Oxid. Med. Cell. Longev. 2022 2022 7616696 10.1155/2022/7616696
141 Yang X. Wang L. Li R. The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2 Biochem. Biophys. Res. Commun. 502 2 2018 262 268 10.1016/j.bbrc.2018.05.157 29803673
142 Chen J. Wang F. Xu H. Long non-coding RNA SNHG1 regulates the Wnt/beta-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell Front. Oncol. 10 2020 552907 10.3389/fonc.2020.552907
143 Jiang Y. Zhao H. Chen Y. Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p/FOXM1 axis Cell Death Dis. 12 12 2021 1129 10.1038/s41419-021-04421-0 34864822
144 Liu Y. Gong Z. Sun L. Li X. FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells Biochim. Biophys. Acta 1839 4 2014 297 305 10.1016/j.bbagrm.2014.02.016 24583551
145 Mo C. Huang B. Zhuang J. LncRNA nuclear-enriched abundant transcript 1 shuttled by prostate cancer cells-secreted exosomes initiates osteoblastic phenotypes in the bone metastatic microenvironment via miR-205-5p/runt-related transcription factor 2/splicing factor proline- and glutamine-rich/polypyrimidine tract-binding protein 2 axis Clin. Transl. Med. 11 8 2021 e493 10.1002/ctm2.493 34459124
146 Chandran U.R. Ma C. Dhir R. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process BMC Cancer 7 2007 64 10.1186/1471-2407-7-64 17430594
147 Desai K. McManus J.M. Sharifi N. Hormonal therapy for prostate cancer Endocr. Rev. 42 3 2021 354 373 10.1210/endrev/bnab002 33480983
148 Guo Z. Lu X. Yang F. Exosomal LINC01213 plays a role in the transition of androgen-dependent prostate cancer cells into androgen-independent manners J. Oncol. 2022 2022 8058770 10.1155/2022/8058770
149 Murillo-Garzon V. Kypta R. WNT signalling in prostate cancer Nat. Rev. Urol. 14 11 2017 683 696 10.1038/nrurol.2017.144 28895566
150 Tang Y. Liu J. Li X. Wang W. Exosomal circRNA HIPK3 knockdown inhibited cell proliferation and metastasis in prostate cancer by regulating miR-212/BMI-1 pathway J. Biosci. 46 3 2021 69 10.1007/s12038-021-00190-2 34313249
151 Ramalinga Malathi Roy Arpita Srivastava Anvesha MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence Oncotarget 6 33 2015 34446 34457 26439987
152 Lukacs R.U. Memarzadeh S. Wu H. Witte O.N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation Cell Stem Cell 7 6 2010 682 693 10.1016/j.stem.2010.11.013 21112563
153 Jiang L. Song L. Wu J. Bmi-1 promotes glioma angiogenesis by activating NF-kappaB signaling PLoS One 8 1 2013 e55527 10.1371/journal.pone.0055527
154 Li T. Sun X. Chen L. Exosome circ_0044516 promotes prostate cancer cell proliferation and metastasis as a potential biomarker J. Cell. Biochem. 121 3 2020 2118 2126 10.1002/jcb.28239 31625175
155 Liao B. Chen S. Li Y. LncRNA BLACAT1 promotes proliferation, migration and invasion of prostate cancer cells via regulating miR-29a-3p/DVL3 Axis Technol. Cancer Res. Treat. 20 2021 1533033820972342 10.1177/1533033820972342
156 Wu K. Woo S.M. Seo S.U. Kwon T.K. Inhibition of BMI-1 induces apoptosis through downregulation of DUB3-mediated Mcl-1 stabilization Int. J. Mol. Sci. 22 18 2021 10107 10.3390/ijms221810107
157 Zhang G. Liu Y. Yang J. Wang H. Xing Z. Inhibition of circ_0081234 reduces prostate cancer tumor growth and metastasis via the miR-1/MAP 3 K1 axis J. Gene Med. 24 8 2022 e3376 10.1002/jgm.3376
158 Odero-Marah V. Hawsawi O. Henderson V. Sweeney J. Epithelial-mesenchymal transition (EMT) and prostate cancer Adv. Exp. Med. Biol. 1095 2018 101 110 10.1007/978-3-319-95693-0_6 30229551
159 Jin M. Zhang T. Liu C. miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells Cancer Res. 74 15 2014 4183 4195 10.1158/0008-5472.CAN-14-0404 24903149
160 Bansal N. Bartucci M. Yusuff S. BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer Clin. Cancer Res. 22 24 2016 6176 6191 10.1158/1078-0432.CCR-15-3107 27307599
161 Zhang H. Li M. Zhang J. Shen Y. Gui Q. Exosomal circ-XIAP promotes docetaxel resistance in prostate cancer by regulating miR-1182/TPD52 Axis Drug Des. Dev. Ther. 15 2021 1835 1849 10.2147/DDDT.S300376
162 Byrne J.A. Frost S. Chen Y. Bright R.K. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol. 35 8 2014 7369 7382 10.1007/s13277-014-2006-x 24798974
163 Ummanni R. Teller S. Junker H. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells FEBS J. 275 22 2008 5703 5713 10.1111/j.1742-4658.2008.06697.x 18959755
164 Zhang D. He D. Xue Y. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway Cancer Res. 71 6 2011 2193 2202 10.1158/0008-5472.CAN-10-1791 21385902
165 Yang Y. Liu K.Y. Liu Q. Cao Q. Androgen receptor-related non-coding RNAs in prostate cancer Front. Cell Dev. Biol. 9 2021 660853 10.3389/fcell.2021.660853
166 Konoshenko M.Y. Bryzgunova O.E. Laktionov P.P. miRNAs and androgen deprivation therapy for prostate cancer Biochim. Biophys. Acta Rev. Canc 1876 2 2021 188625 10.1016/j.bbcan.2021.188625
167 Ghosh R.K. Pandey T. Dey P. Liquid biopsy: a new avenue in pathology Cytopathology 30 2 2019 138 143 10.1111/cyt.12661 30485558
168 Naji L. Randhawa H. Sohani Z. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis Ann. Fam. Med. 16 2 2018 149 154 10.1370/afm.2205 29531107
169 Li Y. Tang X. Deng R. Dumbbell dual-hairpin triggered DNA nanonet assembly for cascade-amplified sensing of exosomal MicroRNA ACS Omega 9 17 2024 19723 19731 10.1021/acsomega.4c02652 38708273
170 Rodriguez M. Bajo-Santos C. Hessvik N.P. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes Mol. Cancer 16 1 2017 156 10.1186/s12943-017-0726-4 28982366
171 Li Z. Li L.X. Diao Y.J. Identification of urinary exosomal miRNAs for the non-invasive diagnosis of prostate cancer Cancer Manag. Res. 13 2021 25 35 10.2147/CMAR.S272140 33442291
172 Bryzgunova O.E. Zaripov M.M. Skvortsova T.E. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients PLoS One 11 6 2016 e0157566 10.1371/journal.pone.0157566
173 Xu Y. Qin S. An T. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method Prostate 77 10 2017 1167 1175 10.1002/pros.23376 28617988
174 Wani S. Kaul D. Mavuduru R.S. Kakkar N. Bhatia A. Urinary-exosomal miR-2909: a novel pathognomonic trait of prostate cancer severity J. Biotechnol. 259 2017 135 139 10.1016/j.jbiotec.2017.07.029 28764970
175 Li W. Dong Y. Wang K.J. Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer Neoplasma 67 6 2020 1314 1318 10.4149/neo_2020_191130N1234 32614237
176 Li Z. Ma Y.Y. Wang J. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients OncoTargets Ther. 9 2016 139 148 10.2147/OTT.S95565
177 Bryant R.J. Pawlowski T. Catto J.W. Changes in circulating microRNA levels associated with prostate cancer Br. J. Cancer 106 4 2012 768 774 10.1038/bjc.2011.595 22240788
178 Li Y. Ji J. Lyu J. A novel urine exosomal lncRNA assay to improve the detection of prostate cancer at initial biopsy: a retrospective multicenter diagnostic feasibility study Cancers 13 16 2021 10.3390/cancers13164075
179 Wang Y.H. Ji J. Wang B.C. Tumor-derived exosomal long noncoding RNAs as promising diagnostic biomarkers for prostate cancer Cell. Physiol. Biochem. 46 2 2018 532 545 10.1159/000488620 29614511
180 Ahadi A. Brennan S. Kennedy P.J. Hutvagner G. Tran N. Long non-coding RNAs harboring miRNA seed regions are enriched in prostate cancer exosomes Sci. Rep. 6 2016 24922 10.1038/srep24922
181 Isin M. Uysaler E. Ozgur E. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease Front. Genet. 6 2015 168 10.3389/fgene.2015.00168 25999983
182 Wu Y. Circ_0044516 enriches the level of SARM1 as a miR-330-5p sponge to regulate cell malignant behaviors and tumorigenesis of prostate cancer Biochem. Genet. 60 4 2022 1346 1361 10.1007/s10528-021-10160-w 34993722
183 Guo T. Wang Y. Jia J. The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing Front. Cell Dev. Biol. 8 2020 602493 10.3389/fcell.2020.602493
184 Huang X. Yuan T. Liang M. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer Eur. Urol. 67 1 2015 33 41 10.1016/j.eururo.2014.07.035 25129854
185 Wang S. Su W. Zhong C. An eight-CircRNA assessment model for predicting biochemical recurrence in prostate cancer Front. Cell Dev. Biol. 8 2020 599494 10.3389/fcell.2020.599494
186 Wei Y. Zhou W. Li X. Coupling hybridization chain reaction with catalytic hairpin assembly enables non-enzymatic and sensitive fluorescent detection of microRNA cancer biomarkers Biosens. Bioelectron. 77 2016 416 420 10.1016/j.bios.2015.09.053 26439017
187 Wang Q. Liu J. Zeng J. Determination of miRNA derived from exosomes of prostate cancer via toehold-aided cyclic amplification combined with HRP enzyme catalysis and magnetic nanoparticles Anal. Biochem. 630 2021 114336 10.1016/j.ab.2021.114336
188 Kim J. Shim J.S. Han B.H. Hydrogel-based hybridization chain reaction (HCR) for detection of urinary exosomal miRNAs as a diagnostic tool of prostate cancer Biosens. Bioelectron. 192 2021 113504 10.1016/j.bios.2021.113504
189 Cho S. Yang H.C. Rhee W.J. Simultaneous multiplexed detection of exosomal microRNAs and surface proteins for prostate cancer diagnosis Biosens. Bioelectron. 146 2019 111749 10.1016/j.bios.2019.111749
190 Xiao G.Y. Cheng C.C. Chiang Y.S. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy Sci. Rep. 6 2016 23120 10.1038/srep23120
191 Khan M. Nickoloff E. Abramova T. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction Circ. Res. 117 1 2015 52 64 10.1161/CIRCRESAHA.117.305990 25904597
192 Li S.P. Lin Z.X. Jiang X.Y. Yu X.Y. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools Acta Pharmacol. Sin. 39 4 2018 542 551 10.1038/aps.2017.178 29417947
193 Shtam T.A. Kovalev R.A. Varfolomeeva E.Y. Exosomes are natural carriers of exogenous siRNA to human cells in vitro Cell Commun. Signal. 11 2013 88 10.1186/1478-811X-11-88 24245560
194 Lamichhane T.N. Jeyaram A. Patel D.B. Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication Cell. Mol. Bioeng. 9 3 2016 315 324 10.1007/s12195-016-0457-4 27800035
195 Ohno S. Takanashi M. Sudo K. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells Mol. Ther. 21 1 2013 185 191 10.1038/mt.2012.180 23032975
196 Li L. He D. Guo Q. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer J. Nanobiotechnol. 20 1 2022 50 10.1186/s12951-022-01264-5
197 Huang X. Wu W. Jing D. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy J. Contr. Release 343 2022 107 117 10.1016/j.jconrel.2022.01.026
198 Yang L. Han B. Zhang Z. Extracellular vesicle-mediated delivery of circular RNA SCMH1 promotes functional recovery in rodent and nonhuman primate ischemic stroke models Circulation 142 6 2020 556 574 10.1161/CIRCULATIONAHA.120.045765 32441115
199 Yamayoshi A. Oyama S. Kishimoto Y. Development of antibody-oligonucleotide complexes for targeting exosomal MicroRNA Pharmaceutics 12 6 2020 10.3390/pharmaceutics12060545
